Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887290 | 0.91 | ALDH1A1 (0.44) | ALDH1A1LMNAAKT1AKT2 | |
| SCHEMBL5886693 | 0.90 | MAPK8 (0.38) | CNR2ALDH1A1LMNANAMPTAKT1 | |
| SCHEMBL5887036 | 0.89 | EPHX2 (0.39) | RORCALDH1A1NAMPT | |
| SCHEMBL5887095 | 0.86 | ALDH1A1 (0.44) | ALDH1A1LMNANAMPT | |
| SCHEMBL5886867 | 0.85 | BRAF (0.48) | BRAFLSSALDH1A1LMNACTNNB1 | |
| SCHEMBL5886837 | 0.85 | KMT2A (0.47) | BRAFLMNAMCHR1 | |
| SCHEMBL5887260 | 0.85 | KMT2A (0.42) | BRAFLMNACTNNB1TCF7L2 | |
| SCHEMBL5886908 | 0.84 | BRAF (0.39) | BRAFRORCNAMPT | |
| SCHEMBL5887202 | 0.84 | BRAF (0.38) | BRAFRORCLSSCNR1CNR2 | |
| SCHEMBL5886703 | 0.84 | NAMPT (0.37) | ALDH1A1CTNNB1TCF7L2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | BRAF 1390/4885RORC 3073/4885LSS 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.